Interestingly, this signature was identified as the best fit for predicting clinical outcome of ET-treated patients (likelihood = 741.46), compared to the models integrating ZNF217 mRNA levels (likelihood = 746.65, P = 0.023) or Ki-67 mRNA levels (likelihood = 749.24, P = 0.005) only. Here, MKI67 is linked to essential thrombocythemia.